September 9th 2021, 7:38pm
The effectiveness of this treatment in patients with multiple myeloma may be an option for a patient population who represent an unmet need.
September 9th 2021, 7:27pm
Various phase 2 and 3 studies are currently underway utilizing both new and existing treatments in an effort to improve outcomes for patients with myelofibrosis.
September 9th 2021, 7:07pm
The first-line combination of durvalumab and chemotherapy, with or without tremelimumab, led to a statistically significant improvement in progression-free survival compared with chemotherapy alone in patients with metastatic non–small cell lung cancer, according to data from the phase 3 POSEIDON trial.
September 9th 2021, 7:03pm
The safety and efficacy of the quadruplet regimen of fixed-dose isatuximab-irfcc in combination with bortezomib, lenalidomide, and dexamethasone were confirmed for patients with newly diagnosed multiple myeloma with no immediate intent for transplant.
September 9th 2021, 6:24pm
Future treatment approaches for patients with polycythemia vera (PV) should center around adapting therapy using the available criteria, and eventually finding new targets.
September 9th 2021, 6:06pm
For patients with myeloma have undergone an autologous stem cell transplant and are currently on maintenance therapy with lenalidomide, minimal residual disease may be a powerful predictor of outcomes.
September 9th 2021, 5:59pm
Older patients with newly diagnosed multiple myeloma who are ineligible for chemotherapy or transplant may derive a greater benefit when treated with daratumumab plus lenalidomide and dexamethasone compared with lenalidomide and dexamethasone.
September 9th 2021, 5:24pm
The addition of venetoclax to fludarabine, cytarabine, idarubicin and G-CSF resulted in high complete response rates and enables a high consolidative allogeneic transplantation rate in patients with newly diagnosed acute myeloid leukemia.
September 9th 2021, 5:15pm
Catherine Callaghan Coombs, MD, discusses the efficacy results of the ongoing phase 1/2 BRUIN study with pirtobrutinib in chronic lymphocytic leukemia.
September 9th 2021, 4:35pm
Iberdomide combined with dexamethasone and either daratumumab, bortezomib, or carfilzomib showed efficacy and tolerability in patients with relapsed or refractory multiple myeloma.
September 9th 2021, 3:42pm
Updated data from a phase 2 trial presented at the 2021 World Conference on Lung Cancer showed that neoadjuvant osimertinib induced a pathologic complete response among patients with surgically resectable EGFR-mutant non–small cell lung cancer.
September 9th 2021, 3:30pm
Mobocertinib demonstrated clinical activity in previously platinum-treated patients with EGFR exon 20 insertion mutation–positive non–small cell lung cancer whether or not they received a prior PD-1/PD-L1 inhibitor.
September 8th 2021, 10:28pm
The cure rate for patients with T-cell acute lymphoblastic leukemia has improved dramatically over the past few decades, with outcomes becoming comparable to what is observed in those with B-cell acute lymphoblastic leukemia.
September 8th 2021, 10:00pm
The combination of ado-trastuzumab emtansine and osimertinib demonstrated minimal antitumor effects on patients with EGFR-mutated non–small cell lung cancer, according to interim data of the phase 2 TRAEMOS trial.
September 8th 2021, 9:27pm
Jorge E. Cortes, MD, discusses emerging therapies in chronic myeloid leukemia.
September 8th 2021, 8:52pm
Selpercatinib demonstrated robust and durable efficacy with a favorable safety profile in Chinese patients with advanced, RET fusion–positive non–small cell lung cancer.
September 8th 2021, 7:55pm
Sotorasib elicited systemic durable anticancer activity with intracranial complete responses and continued intracranial stabilization in patients with KRAS G12C–mutated non–small cell lung cancer and stable brain metastases previously treated with radiation or surgery.
September 8th 2021, 7:25pm
Approximately 20% of patients with malignant pleural mesothelioma were diagnosed with COVID-19 during the first year of the pandemic at the Vall d’Hebron University Hospital, leading to a high hospitalization and mortality rate.
September 8th 2021, 6:49pm
Tislelizumab plus chemotherapy demonstrated clinically meaningful improvements in progression-free survival vs standard of care chemotherapy as a first-line treatment for patients with stage IIIB and those with stage IV advanced squamous non–small cell lung cancer.
September 8th 2021, 6:42pm
The combination of osimertinib plus pelcitoclax demonstrated an acceptable safety profile and preliminary efficacy at the recommended phase 2 dose in patients with EGFR-positive non–small cell lung cancer that is resistant to third-generation EGFR inhibitors or treatment naïve.